2007
DOI: 10.1016/j.jchromb.2007.04.037
|View full text |Cite
|
Sign up to set email alerts
|

Quantitative HPLC-UV method for the determination of firocoxib from horse and dog plasma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
34
3

Year Published

2007
2007
2024
2024

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 27 publications
(37 citation statements)
references
References 27 publications
0
34
3
Order By: Relevance
“…Short-term (benchtop) stability of firocoxib in urine was assessed for fortified samples maintained at room temperature for at least 4 h following one F/T cycle. Stability of firocoxib in plasma was assessed previously in our laboratory [21]. Firocoxib was stable in plasma for at least eight F/T cycles.…”
Section: Stabilitymentioning
confidence: 99%
See 1 more Smart Citation
“…Short-term (benchtop) stability of firocoxib in urine was assessed for fortified samples maintained at room temperature for at least 4 h following one F/T cycle. Stability of firocoxib in plasma was assessed previously in our laboratory [21]. Firocoxib was stable in plasma for at least eight F/T cycles.…”
Section: Stabilitymentioning
confidence: 99%
“…Previously, there were no published methods for the quantitation of firocoxib in plasma. A method to determine the concentrations of firocoxib in plasma, developed and validated in our laboratory, has been submitted for publication [21]. This method uses solid phase extraction followed by LC-UV analysis and has a LLOQ of 25 ng/mL in horse and dog plasma.…”
Section: Introductionmentioning
confidence: 99%
“…17,18 Firocoxib is approved for the control of pain and inflammation associated with OA for up to 14 days. Firocoxib in a paste form (also available in injectable form) has become a commonly prescribed treatment of clinicians for long-term treatment of OA, and more specifically chronic OA.…”
Section: Donnell and Frisbiementioning
confidence: 99%
“…Chemically it is a 3-cyclopropymethoxy-5,5-dimethyl-4-[4-(methyl sulfonyl) phenyl]-2-(5H)-furanone and its molecular weight is 336.402 g moL −1 . The drug was launched several years ago and in this short time, the pharmacokinetic properties of firocoxib in dogs and horses have already been well established (Kvaternick et al, 2007a;2007b;Letendre et al, 2008). Firocoxib is available as a chewable tablet oral preparation which has been approved in the European Union for dogs at a once daily administration of 5 mg kg −1 .…”
Section: Firocoxibmentioning
confidence: 99%
“…In addition, firocoxib, as an oral paste was approved by FDA for the control of pain and inflammation associated with osteoarthritis in horses at 0.1 mg kg −1 once daily (Kvaternick et al, 2007b). In dogs, following PO administration (5 mg kg −1 ), firocoxib was well absorbed and eliminated by hepatic metabolism and fecal excretion with an elimination half-life of 8 h (Kvaternick et al, 2007a). Firocoxib in horses (0.1 mg kg −1 ) showed a bioavailability of 79% and an elimination half-life of 30 and 34 h for oral and intravenous administration, respectively.…”
Section: Firocoxibmentioning
confidence: 99%